Physician profile
David E Hrncir
NPI 1023080124
$7,221.90
in general payments reported to CMS, 2019-2025
29 companies · $1,095 in 2025
The $1,095 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $411 · 2021: $908 · 2022: $1,370 · 2023: $1,659 · 2024: $1,558 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.89 |
| Education | $212.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,304.96 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Sanofi-Aventis U.S. LLC | $1,208.94 | 2021-2025 | |
| Genzyme Corporation | $848.76 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $559.74 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $510.33 | 2020-2024 | Xolair |
| Alk-Abello, INC | $355.79 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $282.48 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.44 | 2019-2025 | Dupixent |
| Octapharma USA, INC. | $182.76 | 2021-2025 | Cutaquig, Panzyga |
| Blueprint Medicines Corporation | $150.97 | 2022-2024 | Ayvakit |
| Grifols USA, LLC | $150.62 | 2021-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $147.38 | 2025 | Neffy |
| Kaleo, INC. | $137.29 | 2020-2023 | Auvi-Q |
| Biohaven Pharmaceutical Holding Company Ltd. | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.59 | 2020-2025 | Cuvitru |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $115.87 | 2019-2025 | Ruconest |
| Csl Behring | $102.39 | 2020-2025 | Haegarda, Andembry, Hizentra |
| Optinose US, INC. | $101.61 | 2019-2021 | |
| Amgen INC. | $96.42 | 2021-2023 | Tezspire |
| Greer Laboratories, INC. | $91.93 | 2022-2024 | Oralair |
| Pfizer INC. | $67.26 | 2023 | |
| Incyte Corporation | $62.61 | 2021-2022 | |
| Covis Pharma Gmbh | $60.73 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $52.23 | 2022-2025 | Ryaltris |
| Baxter Healthcare | $32.62 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Gc Biopharma USA, INC. | $27.59 | 2025 | Alyglo |
| Adma Biomanufacturing LLC | $26.41 | 2020-2021 | |
| Kedrion Biopharma, INC. | $17.34 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Circassia INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hrncir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.